Login to Your Account

Prime time: Kairos buyout adds to oncology program as Zymeworks nears the clinic

By Randy Osborne
Staff Writer

Tuesday, March 22, 2016

"We're not done," Zymeworks Inc. CEO Ali Tehrani told BioWorld Today as the firm disclosed its takeover of Kairos Therapeutics Inc. to bring aboard a next-generation ADC technology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription